Key result
In terminally ill cancer patients, heart rate variability measured by SDNN was a significant independent prognostic factor for survival duration.
Why the study?
Does heart rate variability predict survival duration in terminally ill hospice cancer patients?
Cohort (n=68)
No
Does heart rate variability predict survival duration in terminally ill hospice cancer patients?
Heart rate variability, specifically SDNN, serves as a significant independent prognostic factor for survival duration in terminal cancer patients.
Answers are grounded in this paper and cite their sources.
SDNN may refine survival estimates in terminal cancer hospice care; leaves open whether it improves decision-making or requires prospective validation.
We examined the association between heart rate variability (HRV) and survival duration to evaluate the usefulness of HRV as a prognostic factor for hospice cancer patients. In terminally ill cancer patients who visited the Hospice clinic, we checked demographic data, Karnofsky performance scale (KPS), HRV, dyspnea, anorexia, as well as fasting blood glucose and total cholesterol. After following up their duration of survival, we examined meaningful prognostic factors for predicting life expectancy through the survival analysis. A total of 68 patients were included in final analysis. As KPS was lower, or when combined with dyspnea or anorexia, the survival duration was much shorter. HRV parameters except heart rate were all impaired in most patients. In particular, the group with mean heart rate of 100 or more beats per minute and the group with standard deviations of normal-to-normal R-R intervals (SDNN) of 21.3 ms (75 percentile) or less showed significantly shorter survival duration. The final multivariate analysis adjusting for age, gender, fasting blood glucose, and total cholesterol showed that KPS, dyspnea, anorexia, and SDNN were significant prognostic factors in survival duration. For the first time, we report that SDNN is a prognostic factor in terminal cancer patients.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2010) conducted a cohort in Terminal cancer (n=68). Heart rate variability (SDNN) vs. Higher SDNN was evaluated on Survival duration (HR 0.062, 95% CI 0.006-0.673, p=0.022). In terminally ill cancer patients, heart rate variability measured by SDNN was a significant independent prognostic factor for survival duration.
Synapse has enriched 10 related papers. Consider them for comparative context: